Literature DB >> 6848296

Lorcainide disposition kinetics in arrhythmia patients.

R E Kates, D L Keefe, R A Winkle.   

Abstract

Lorcainide disposition kinetics were studied after intravenous and oral administration to patients with ventricular arrhythmias. After intravenous doses ranging from 100 to 200 mg, blood samples were drawn and plasma was analyzed for lorcainide concentration by high-pressure liquid chromatography. A three-compartment model was used to fit the data. The model-independent calculated values for clearance, steady-state volume of distribution, and terminal half-life were 14.4 +/- 3.28 ml/min/kg, 6.33 +/- 2.23 l/kg, and 7.8 +/- 2.2 hr. After nine doses of oral lorcainide (100 mg every 12 hr) blood samples were drawn and analyzed for lorcainide and its active metabolite, norlorcainide. The lorcainide and norlorcainide half-lifes were 9.6 +/- 2.8 and 26.8 +/- 8.2 hr. Mean steady-state level of norlorcainide was 2.2 +/- 0.9 times the level of lorcainide. The data suggest that the clearance of lorcainide decreases with time during long-term dosing.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6848296     DOI: 10.1038/clpt.1983.4

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  Drug interaction between lorcainide and rifampicin.

Authors:  V F Mauro; P Somani; P N Temesy-Armos
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 2.  Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  C e Eiriksson; R N Brogden
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

Review 4.  First-pass elimination. Basic concepts and clinical consequences.

Authors:  S M Pond; T N Tozer
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

Review 5.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

6.  Identification of a prazosin metabolite and some preliminary data on its kinetics in hypertensive patients.

Authors:  V K Piotrovskii; N N Veiko; O S Ryabokon; S F Postolnikov; V I Metelitsa
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.